Bicyclic heterocycles as cannabinoid receptor modulators

Details Bicyclic heterocycles as cannabinoid receptor modulators Bicyclic heterocycles as cannabinoid receptor modulators

2008-04-22

2008-04-22

Seaman, Margaret D. (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

07361766

ABSTRACT:
The present application describes compounds according to Formula I, pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents and methods of treatment using the compounds according to Formula I both alone and in combination with one or more additional therapeutic agents. The compounds have the general Formula I:including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R3a, R4, A, B, b, n, W, X, Y and Z are described herein.

REFERENCES:
patent: 3674836 (1972-07-01), Creger
patent: 3983140 (1976-09-01), Endo et al.
patent: 4027009 (1977-05-01), Grier et al.
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4379785 (1983-04-01), Weyer et al.
patent: 4448784 (1984-05-01), Glamkowski et al.
patent: 4450171 (1984-05-01), Hoffman et al.
patent: 4499289 (1985-02-01), Baran et al.
patent: 4613610 (1986-09-01), Wareing
patent: 4639436 (1987-01-01), Junge et al.
patent: 4647576 (1987-03-01), Hoefle et al.
patent: 4681893 (1987-07-01), Roth
patent: 4686237 (1987-08-01), Anderson
patent: 4759923 (1988-07-01), Buntin et al.
patent: 4871721 (1989-10-01), Biller
patent: 4904769 (1990-02-01), Rauenbusch
patent: 4924024 (1990-05-01), Biller
patent: 5006530 (1991-04-01), Angerbauer et al.
patent: 5011930 (1991-04-01), Fujikawa et al.
patent: 5177080 (1993-01-01), Angerbauer et al.
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5273995 (1993-12-01), Roth
patent: 5354772 (1994-10-01), Kathawala
patent: 5385929 (1995-01-01), Bjorge et al.
patent: 5447954 (1995-09-01), Gribble et al.
patent: 5488064 (1996-01-01), Sher
patent: 5491134 (1996-02-01), Sher et al.
patent: 5506219 (1996-04-01), Robl
patent: 5541204 (1996-07-01), Sher et al.
patent: 5594016 (1997-01-01), Ueno et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5686104 (1997-11-01), Mills et al.
patent: 5691322 (1997-11-01), Robl
patent: 5698527 (1997-12-01), Kim
patent: 5712396 (1998-01-01), Magnin et al.
patent: 5753675 (1998-05-01), Wattanasin
patent: 5770615 (1998-06-01), Cheng et al.
patent: 5776983 (1998-07-01), Washburn et al.
patent: 5990109 (1999-11-01), Chen et al.
patent: 6043265 (2000-03-01), Murugesan et al.
patent: 6184231 (2001-02-01), Hewawasam et al.
patent: 6414002 (2002-07-01), Cheng et al.
patent: 6635626 (2003-10-01), Barrish et al.
patent: 2004/0171613 (2004-09-01), Iwamura et al.
patent: 2006/0154955 (2006-07-01), Sun et al.
patent: 2006/0155126 (2006-07-01), Sun et al.
patent: 196 22 222 (1996-06-01), None
patent: 0 221 025 (1987-05-01), None
patent: 0 142 146 (1988-08-01), None
patent: 0 675 714 (1999-01-01), None
patent: 1 142 877 (2001-10-01), None
patent: 0 818 448 (2003-11-01), None
patent: 1 022 272 (2004-05-01), None
patent: 0 992 496 (2005-08-01), None
patent: 2 596 393 (1986-05-01), None
patent: 2 205 837 (1988-12-01), None
patent: 2 304 106 (1997-03-01), None
patent: WO 86/03488 (1986-06-01), None
patent: WO 86/07054 (1986-12-01), None
patent: WO 94/15592 (1994-07-01), None
patent: WO 97/21993 (1997-06-01), None
patent: WO 97/35576 (1997-10-01), None
patent: WO 97/48701 (1997-12-01), None
patent: WO 99/00353 (1999-01-01), None
patent: WO 00/01389 (2000-01-01), None
patent: WO 00/15201 (2000-03-01), None
patent: WO 00/30665 (2000-06-01), None
patent: WO 00/38722 (2000-07-01), None
patent: WO 00/50574 (2000-08-01), None
patent: WO205/007111 (2005-01-01), None
patent: WO2005/007628 (2005-01-01), None
Biller, S. et al., “Squalene Synthase Inhibitors”, Current Pharmaceutical Design, vol. 2, pp. 1-40 (1996).
Biller, S. et al., “Isoprenoid (Phosphinylmethyl) phosphonates as Inhibitors of Squalene Synthetase”, J. of Medicinal Chemistry, vol. 31(10), pp. 1869-1871 (1988).
Colombo, G. et al., “Appetite Suppression and Weight Loss after the Cannabinoid Antagonist SR 141716”, Life Sciences, vol. 63(8), pp. PL 113-117 (1998).
Corey, E. et al., “Application of Unreactive Analogs of Terpenoid Pyrophosphates to Studies of Multistep Biosynthesis. Demonstration that “Presqualene Pyrophosphate” is an Essential Intermediate on the Path to Squalene”, J. of the American Chemical Society, vol. 98(5), pp. 1291-1293 (19761).
Davidsen,S. et al., “N-(Acyloxyalkyl) pyridinium Salts as Soluble Prodrugs of a Potent Platelet Activating Factor Antagonist”, J. of Medicinal Chemistry, vol. 37(26), pp. 4423-4429 (1994).
DiMarzo, V. et al., “Leptin-regulated endocannabinoids are involved in maintaining food intake”, Nature, vol. 410, pp. 822-825 (2001).
Ettmayer, P. et al., “Lessons Learned from Marketed and Investigational Prodrugs”, J. of Medicinal Chemistry, vol. 47(10), pp. 2393-2404 (2004).
Galiegue, S. et al., “Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations”, Eur. J. Biochem., vol. 232, pp. 54-61 (1995).
Ghiselli, G., “The Pharmacological Profile of FCE 27677: A Novel ACAT Inhibitor with Potent Hypolipidemic Activity Mediated by Selective Suppression of the Hepatic Secretion of ApoB-100-Containing Lipoprotein”, Cardiovascular Drug Reviews, vol. 16(1), pp. 16-30 (1998).
Glass, M. et al., “Cannabinoid Receptors in the Human Brain: A Detailed Anatomical and Quantitative Autoradiographic Study in the Fetal, Neonatal and Adult Human Brain”, Neuroscience, vol. 77(2), pp. 299-318 (1997).
Hara, S., “Ileal Na+/bile acid cotransporter inhibitors”, Drugs of the Future, vol. 24(4), pp. 425-430 (1999).
Hildebrandt, A. et al. “Antiobesity effects of chronic cannabinoid CB1receptor antagonist treatment in diet-induced obese mice”, European J. of Pharmacology, vol. 462, pp. 125-132 (2003).
Hollenbaugh, D. et al., “Cleavable CD40lg fusion proteins and the binding to sgp39”, J. of Immunological Methods, vol. 188, pp. 1-7 (1995).
Hollenbaugh, D. et al. “The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity”, The EMBO Journal, vol. 11(12), pp. 4313-4321 (1992).
Krause, B. et al., “ACAT Inhibitors: Physiologic Mechanisms for Hypolipidemic and Anti-Atherosclerotic Activities in Experimental Animals”, Inflammation: Mediators and Pathways, pp. 173-198 (1995).
Ljung, B. et al., “AZ 242, a novel PPARα/γ agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats”, J. of Lipid Research, vol. 43, pp. 1855-1863 (2002).
Matsuda, L. et al. “Structure of a cannabinoid receptor and functional expression of the cloned cDNA”, Nature, vol. 346, pp. 561-563 (1990).
McClard, R. et al., “Novel Phosphonylphosphinyl (P-C-P-C-) Analogues of Biochemically Interesting Diphosphates. Syntheses and Properties of P-C-P-C- Analogues of Isopentenyl Diphosphate and Dimethylallyl Diphosphate”, J. Am. Chem. Soc., vol. 109, pp. 5544-5545 (1987).
Moreland, L. et al., “Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)-Fc Fusion Protein”, The New England J. of Medicine, vol. 337(3), pp. 141-147 (1997).
Munro, S. et al., “Molecular characterization of a peripheral receptor for cannabinoids”, Nature, vol. 365, pp. 61-65 (1993).
Nicolosi, R. et al., “The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters”, Atherosclerosis, vol. 137, pp. 77-85 (1998).
Ortiz de Montellano, P. et al., “Inhibition of Squalene Synthetase by Farnesyl Pyrophosphate Analogues”, J. of Medicinal Chemistry, vol. 20(2), pp. 243-249 (1977).
Rosenblum, S. et al., “Discovery of 1-(4-Flurophenyl)-(3R)-[3-(4-flurophenyl)-(3S)-hydroxyprophyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption”, J. Med.

Affiliated with

Also associated with

Rating

Bicyclic heterocycles as cannabinoid receptor modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bicyclic heterocycles as cannabinoid receptor modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bicyclic heterocycles as cannabinoid receptor modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2762083